Skip to main content
. Author manuscript; available in PMC: 2021 Dec 30.
Published in final edited form as: Oncogene. 2021 Jun 30;40(32):5095–5104. doi: 10.1038/s41388-021-01843-0

Figure 5. Viability of hES-derived mesenchymal cells expressing EWSR1-CREB1 and EWSR1-ATF1 while maintaining the AFH and CCS core gene signatures.

Figure 5.

(A) hES-MP cells express mesenchymal surface markers CD73 and CD105. EWSR1(ex7)-CREB1(ex7) and EWSR1(ex7)-ATF1(ex5) refer to cells carrying the translocation prior to Cre expression.

(B) Time course in days of EWSR1-CREB1 fusion expression in hES-MP cells after Cre expression. The AFH core gene signature is detected in hES-MP cells expressing the EWSR1(ex7)-CREB1(ex7) fusion over time. Histogram represents the fold increase compared to wild type cells (-Cre condition) and the error bars the standard deviation from the mean of 4 independent experiments. Statistical significance is calculated with a paired t-test comparing +Cre with the corresponding -Cre condition. *p<0.05, **p<0.01; when not indicated the difference is considered not statistically significant.

(C) Same as panel B for the EWSR1(ex7)-ATF1(ex5) fusion. qRT-PCR in hES-MP cells expressing the EWSR1(ex7)-ATF1(ex5) at different time points. Statistical analysis as in panel B, n=5. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.